Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Survival Tree01:19

Survival Tree

418
Survival trees are a non-parametric method used in survival analysis to model the relationship between a set of covariates and the time until an event of interest occurs, often referred to as the "time-to-event" or "survival time." This method is particularly useful when dealing with censored data, where the event has not occurred for some individuals by the end of the study period, or when the exact time of the event is unknown.
 Building a Survival Tree
Constructing a...
418
Survival Curves01:18

Survival Curves

696
Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
696
Gene Flow02:39

Gene Flow

37.7K
Gene flow is the transfer of genes among populations, resulting from either the dispersal of gametes or from the migration of individuals.
37.7K
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

765
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
765
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

583
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
583
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

611
Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
611

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of the orexin receptor antagonist, suvorexant, on sleep architecture in the early postoperative period following cardiac surgery: a randomized controlled trial.

Critical care (London, England)·2026
Same author

Contemporary Outcomes of Temporary Mechanical Circulatory Support Use in Ischemic Ventricular Septal Defect: A U.S. Multi-Center Analysis.

The Annals of thoracic surgery·2026
Same author

Machine Learning Based Prediction of Hospital Mortality in Post-Cardiotomy Cardiogenic Shock with Mechanical Support.

ESC heart failure·2026
Same author

Stented vs. stentless in aortic stenosis: a systematic review and meta-analysis.

Journal of cardiothoracic surgery·2026
Same author

Efficacy and safety of intravenous lidocaine in thyroidectomy: a systematic review and meta-analysis with trial sequential analysis and meta-regression.

BMC anesthesiology·2026
Same author

Trends, center level practice, and outcomes of heart transplantation in people with HIV.

JHLT open·2026

Related Experiment Video

Updated: Jan 28, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.6K

Continuous-Flow Left Ventricular Assist Device Survival Improves With Multidisciplinary Approach.

Ulrich P Jorde1, Aman M Shah1, Daniel B Sims1

  • 1Department of Internal Medicine, Division of Cardiovascular Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York.

The Annals of Thoracic Surgery
|March 12, 2019
PubMed
Summary

A multidisciplinary heart team approach significantly improved survival and reduced adverse events in patients with advanced heart failure receiving HeartMate II continuous-flow left ventricular assist devices.

More Related Videos

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.1K

Related Experiment Videos

Last Updated: Jan 28, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.6K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.1K

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Mechanical Circulatory Support

Background:

  • Continuous-flow left ventricular assist devices (CF-LVADs) are crucial for advanced heart failure management.
  • Device complications remain a challenge, impacting patient survival.
  • Enhanced management strategies are vital for improving CF-LVAD outcomes.

Purpose of the Study:

  • To compare outcomes of HeartMate II recipients before and after implementing a multidisciplinary heart team (HTMCS) strategy.
  • To evaluate the impact of a structured, team-based approach on CF-LVAD patient care.
  • To assess the effectiveness of specific interventions within the HTMCS strategy.

Main Methods:

  • A retrospective study comparing 124 HeartMate II recipients (2012-2016).
  • Implementation of a HTMCS strategy in January 2015, including daily rounds, pharmacist-directed anticoagulation, and specialized clinics.
  • One-year follow-up for all patients to assess survival and adverse events.

Main Results:

  • One-year survival improved significantly from 74.6% (pre-HTMCS) to 100% (HTMCS) (p=0.0002).
  • Rates of disabling stroke decreased significantly (0.15 vs 0 events/patient-year, p=0.019).
  • Survival free of serious adverse events showed a trend toward improvement (70.4% vs 84.9%, p=0.059).

Conclusions:

  • A comprehensive multidisciplinary heart team approach substantially improved outcomes for CF-LVAD recipients.
  • The HTMCS strategy demonstrates significant benefits in survival and complication reduction.
  • This model of care offers a promising pathway for optimizing CF-LVAD therapy.